BESPALOV, ANTON,JONGEN-RELO, ANA LUCIA,UNGER, LILIANE,DRESCHER, KARLA,LANGE, UDO,BRAJE, WILFRIED,HAUPT, ANDREAS,TURNER, SEAN COLM
申请号：
NZ58209508
公开号：
NZ582095A
申请日:
2008.10.30
申请国别(地区):
NZ
年份:
2012
代理人:
摘要：
The disclosure relates to N-(6-piperazin-1-ylpyridin-3-yl)benzenesulfonamide compound of formula (I), wherein R1 is selected from the group consisting of hydrogen, linear C1-C3 alkyl and fluorinated linear C1-C3 alkyl R2 is hydrogen or methyl R3 is selected from the group consisting of hydrogen, halogen, C1-C2-alkyl, fluorinated C1-C2-alkyl, C1-C2-alkoxy and fluorinated C1-C2-alkoxy, R4 is C1-C2-alkyl or fluorinated C1-C2-alkyl n is 0, 1 or 2, and the physiologically tolerated salts of these compounds and the N-oxides thereof. The disclosure also relates to a pharmaceutical composition that comprises at least one compound of the formula (I) and/or at least one physiologically tolerated acid addition salt thereof, and further to the use an effective amount of at least one compound or physiologically tolerated acid addition salt of the formula (I) for treating disorders that respond beneficially to dopamine D3 receptor antagonists or dopamine D3 agonists, wherein the disorders include a disorder of the central nervous system such as schizophrenia, drug addiction and diabetic nephropathy.
